Arc Bio Joins Microbiome Therapeutics Innovation Group
WASHINGTON, Feb. 9, 2022 /PRNewswire/ -- The MicroBiome Therapeutics LLC (MTIG) today announced the addition of Arc Bio to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products.
Arc Bio is revolutionizing microbial profiling with its Research Use Only (RUO) Galileo™ platform, a novel and proprietary solution empowering researchers and laboratorians to implement metagenomic Next-Generation Sequencing (mNGS) in their own facility. With the commercial launch of their first product Galileo™ ONE, slated for Q2 this year, end users will be able to perform fast, accurate and cost-effective microbial detection and quantification of over 1300 microbial species, including DNA and RNA viruses, bacteria, fungi, and parasites directly on a primary liquid sample type.
"Arc Bio is excited to join Microbiome Therapeutics Innovation Group and lend our expertise in microbial profiling to support our shared mission of accelerating research and development of microbiome-based products and expanding access of these life-saving products to doctors and patients," commented CEO of Arc Bio, Dr. Todd Dickinson.
"We are pleased to welcome Arc Bio to our coalition," said Ken Blount, Ph.D., Chief Scientific Officer of Rebiotix Inc., Vice President of Microbiome Research at Ferring Pharmaceuticals and Chairman of MTIG. "As our second member focused on diagnostics, we look forward to their invaluable knowledge and expertise of microbial detection and analyses, a critical component of the rapidly emerging microbiome therapeutics market."
All pharmaceutical and biotechnology companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products are eligible for consideration of membership in MTIG. If you are interested in learning more about becoming a member of MTIG, please contact us here.
About Arc Bio
Arc Bio aims to create a healthier world by delivering robust sample-to-report microbial profiling workflows combined with data-driven health intelligence software tools to enable a new standard of care for disease detection and monitoring. Its Galileo™ platform represents the next generation of turnkey metagenomics solutions that combine next generation sequencing laboratory workflows with automated bioinformatics pipelines to deliver accurate, comprehensive, and quantitative microbial profiling. Arc Bio is based in Scotts Valley, California and Cambridge, Massachusetts. For more information on Arc Bio, its technology and its service offerings visit www.arcbio.com.
The Galileo™ platform and Galileo™ ONE workflow are research use only and not intended for use in clinical diagnostics and patient management.
About The Microbiome Therapeutics Innovation Group
View original content:https://www.prnewswire.com/news-releases/arc-bio-joins-microbiome-therapeutics-innovation-group-301478039.html
SOURCE Microbiome Therapeutics Innovation Group (MTIG)